Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the R&D spend buried in a 300-page report or tracing how device recalls affect margins can slow any analysis. Dentsply Sirona SEC filings explained simply is exactly what busy investors need.
Our platform ingests every Dentsply Sirona annual report 10-K simplified, Dentsply Sirona quarterly earnings report 10-Q filing, and surprise notice so you see the essentials first. Stock Titan’s AI highlights which product lines—consumables, CAD/CAM, or imaging—drove revenue shifts, and flags any Dentsply Sirona 8-K material events explained within minutes of hitting EDGAR. Need deeper context? Click for a concise Dentsply Sirona earnings report filing analysis that breaks out geographic sales and regulatory commentary.
Monitoring management moves is just as seamless. Receive alerts on Dentsply Sirona insider trading Form 4 transactions and watch Dentsply Sirona Form 4 insider transactions real-time to spot buying or selling patterns before the market reacts. Our dashboards also chart Dentsply Sirona executive stock transactions Form 4 against upcoming product launches, while the latest Dentsply Sirona proxy statement executive compensation is distilled into clear compensation ratios.
Whether you’re understanding Dentsply Sirona SEC documents with AI for a valuation model or verifying compliance disclosures, Stock Titan delivers every filing type—10-K, 10-Q, 8-K, S-8, DEF 14A—backed by AI-powered summaries, keyword search, and real-time updates. Spend less time parsing, and more time deciding.
DENTSPLY SIRONA (XRAY) director filed a Form 4 reporting RSU dividend equivalents. On 10/10/2025, the reporting person acquired 286.094 restricted stock units as dividends on existing RSUs at a price of $0. Following this transaction, beneficial ownership stands at 40,897.4765 shares, held directly.
The company states these are dividends on RSUs awarded to the reporting person, delivered as additional RSUs that carry the same vesting terms as the underlying awards. Each RSU converts to common stock on a 1:1 basis, and the dividend RSUs vest simultaneously with the related RSUs.
DENTSPLY SIRONA (XRAY) director Brian T. Gladden reported an automatic credit of 286.094 additional RSUs on 10/10/2025 at $0, reflecting dividend equivalents on prior RSU awards. Each RSU converts 1:1 into common stock and follows the same vesting schedule as the underlying awards. After this entry, his beneficial ownership stood at 28,726.563 shares, held directly.
DENTSPLY SIRONA (XRAY) director reported an equity change tied to restricted stock units. On 10/10/2025, the reporting person acquired 223.681 RSU dividend equivalents at $0. According to the footnote, these represent dividends on RSUs credited as additional RSUs, vesting on the same schedule as the underlying awards, with each RSU converting to common stock on a 1:1 basis.
Following this transaction, the reporting person beneficially owned 17,699.171 shares, held directly.
DENTSPLY SIRONA (XRAY) reported an insider transaction by its EVP & CFO. On 10/10/2025, the officer acquired 556.226 shares (Transaction Code A) at $0. A footnote explains these represent dividend equivalents on previously granted RSUs, issued as additional RSUs that vest on the same schedule as the underlying awards and convert to common stock on a 1:1 basis.
After this transaction, the reporting person beneficially owned 44,011.347 shares, held directly.
DENTSPLY SIRONA (XRAY) director reported routine equity accruals. On 10/10/2025, the reporting person acquired 359.576 shares of common stock at $0 as dividend equivalents on previously granted RSUs. Following this transaction, directly held common stock totaled 28,451.376 shares.
The filing also shows an acquisition of 123.3618 units of phantom stock under the Directors' Deferred Compensation plan at a derivative price of $11.98. Phantom stock represents the economic equivalent of common stock and becomes payable in shares upon the director’s termination of service. After this accrual, the director held 11,743.5642 phantom stock units.
Notes clarify these were dividend-related accruals for RSUs and phantom stock, with RSUs converting to common stock on a 1:1 basis and phantom stock payable in common stock upon termination.
DENTSPLY SIRONA (XRAY) director reported an equity accrual. On 10/10/2025, the reporting person acquired 179.449 units at $0, reflecting dividends credited on previously awarded RSUs that carry the same vesting terms. Each RSU converts to common stock on a 1:1 basis.
Following this transaction, beneficial ownership stood at 48,005.925 on a direct basis. These credits represent routine dividend equivalents tied to outstanding RSUs rather than open‑market purchases.
DENTSPLY SIRONA (XRAY): Form 4 insider transaction by a director. On 10/10/2025, 310.397 shares of common stock were acquired at $0 as dividends on restricted stock units credited to a Family Partnership. Following this, beneficial holdings were 24,357.397 shares indirect by Family Partnership, 82,301.434 shares direct, and 21,000 shares indirect by a Gregory Lucier IRA.
On 10/14/2025, the reporting person made a gift (Code G) of 17,200 non‑qualified stock options with a $12.96 exercise price to a Family Partnership. These options are exercisable beginning 08/08/2026 and expire on 08/08/2035. The filing notes the gift and includes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.
DENTSPLY SIRONA (XRAY) reported an insider equity change by director Betsy D. Holden. On 10/10/2025, the filing lists Common Stock acquired under code “A” totaling 646.937 at $0. The footnote explains these reflect dividend equivalents on restricted stock units (RSUs) credited as additional RSUs, which vest on the same schedule as the underlying awards, and each RSU converts to common stock on a 1:1 basis. Following the transaction, Holden beneficially owned 53,902.896 shares, held directly.
DENTSPLY SIRONA (XRAY)766.323 shares of common stock on 10/10/2025 at $0 (code A) from dividends on previously awarded RSUs that vest with the underlying awards. Following the transaction, directly held common stock was 85,183.54 shares.
He also acquired 80.9848 shares of phantom stock under the Supplemental Executive Retirement Plan at a derivative price of $11.98, bringing directly held phantom units to 6,142.9981. Each RSU and phantom unit is equivalent to one share of common stock, with phantom stock payable upon termination of employment.
DENTSPLY SIRONA (XRAY) executive Kevin Czerney, VP and Chief Accounting Officer, reported routine equity accruals. On 10/10/2025, he acquired 233.911 RSUs as dividend equivalents at $0, which vest on the same schedule as the underlying RSUs.
Following these transactions, his direct beneficial ownership of common stock is 27,264.0691 shares. The filing notes this includes 112.5060 shares acquired through dividend reinvestment on 10/10/2025.
He was also credited 45.4596 phantom stock units under the SERP and 4.4453 phantom stock units under the DSSP at $11.98 per unit, each economically equivalent to one common share and payable in common stock upon termination of employment.
FAQ
What is the current stock price of Dentsply Sirona (XRAY)?
What is the market cap of Dentsply Sirona (XRAY)?
